Literature DB >> 3087862

Effect of recombinant interferon alpha 2 on clinical course of first episode genital herpes infection and subsequent recurrences.

J Mendelson, B Clecner, S Eiley.   

Abstract

Herpes genitalis is an infection associated with considerable morbidity. Acyclovir, though effective, must be taken daily to prevent recurrences. The effects of interferon on this infection were therefore investigated. In a randomised double blind study, 31 patients with first episodes of genital herpes infection were studied to assess the effect of interferon on the presenting episode and on recurrences. Interferon (5 X 10(6) IU) was administered once daily subcutaneously during a five day "treatment" period followed by a three month "maintenance" period (1 X 10(6) IU three times weekly). Interferon had no effect on first episode herpetic attacks. During interferon administration women showed a trend towards reduced healing time and viral shedding in recurrences, but the differences were not significant and no effect was noted in women after administration of interferon. Interferon reduced assessed healing time and viral shedding in recurrences, however, in men (p = 0.05) during interferon administration, and this continued as a trend after treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087862      PMCID: PMC1011908          DOI: 10.1136/sti.62.2.97

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  6 in total

1.  Prophylactic oral acyclovir in recurrent genital herpes.

Authors:  A Mindel; I V Weller; A Faherty; S Sutherland; D Hindley; A P Fiddian; M W Adler
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

2.  Acyclovir therapy for genital herpes: enthusiasm and caution in equal doses.

Authors:  W L Whittington; W J Cates
Journal:  JAMA       Date:  1984-04-27       Impact factor: 56.272

3.  Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections.

Authors:  L Corey; J K Benedetti; C W Critchlow; M R Remington; C A Winter; A L Fahnlander; K Smith; D L Salter; R E Keeney; L G Davis; M A Hintz; J D Connor; K K Holmes
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

4.  A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection.

Authors:  J M Douglas; C Critchlow; J Benedetti; G J Mertz; J D Connor; M A Hintz; A Fahnlander; M Remington; C Winter; L Corey
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

5.  Topical acyclovir in the treatment of initial genital herpes.

Authors:  R N Thin; J M Nabarro; J D Parker; A P Fiddian
Journal:  Br J Vener Dis       Date:  1983-04

6.  Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects.

Authors:  Y J Bryson; M Dillon; M Lovett; G Acuna; S Taylor; J D Cherry; B L Johnson; E Wiesmeier; W Growdon; T Creagh-Kirk; R Keeney
Journal:  N Engl J Med       Date:  1983-04-21       Impact factor: 91.245

  6 in total
  3 in total

1.  Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences.

Authors:  M J Levin; F N Judson; L Eron; Y J Bryson; L Corey; M Murray; R R Scheer
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Human leukocyte interferon-alpha in cream for the management of genital herpes in Asian women: a placebo-controlled, double-blind study.

Authors:  T A Syed; S Lundin; K M Cheema; R C Kahlon; M Khayyami; S A Ahmad; S H Ahmad; B M Kahlon; A M Kahlon
Journal:  J Mol Med (Berl)       Date:  1995-03       Impact factor: 4.599

3.  The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study.

Authors:  Katharine Jane Looker; Christine Johnston; Nicky J Welton; Charlotte James; Peter Vickerman; Katherine M E Turner; Marie-Claude Boily; Sami L Gottlieb
Journal:  BMJ Glob Health       Date:  2020-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.